Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors

Authors

Kyriakos P. Papadopoulos, South Texas Accelerated Research Therapeutics
Manish R. Sharma, South Texas Accelerated Research Therapeutics
Erika Hamilton, Sarah Cannon Research Institute/Tennessee Oncology
Debra Richardson, Stephenson Cancer Center; Sarah Cannon Research Institute
Babar Bashir, Thomas Jefferson UniversityFollow
Graeme Hodgson, Syros Pharmaceuticals
Nan Ke, Syros Pharmaceuticals
Qing Kang-Fortner, Syros Pharmaceuticals
Li Zhou, Syros Pharmaceuticals
William Zamboni, Syros Pharmaceuticals
Hina A. Jolin, Syros Pharmaceuticals
Catherine Madigan, Syros Pharmaceuticals
Michael J. Kelly, Syros Pharmaceuticals
David A. Roth, Syros Pharmaceuticals

Document Type

Abstract

Publication Date

10-26-2020

Comments

Presented at the EORTC-NCI-AACR Symposium 2020

Recommended Citation

Papadopoulos, Kyriakos P.; Sharma, Manish R.; Hamilton, Erika; Richardson, Debra; Bashir, Babar; Hodgson, Graeme; Ke, Nan; Kang-Fortner, Qing; Zhou, Li; Zamboni, William; Jolin, Hina A.; Madigan, Catherine; Kelly, Michael J.; and Roth, David A., "Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors" (2020). Department of Medical Oncology Faculty Papers. Paper 134.
https://jdc.jefferson.edu/medoncfp/134

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English